The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1535
Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)
The full article is available to subscribers Subscriber Login   

The FDA has approved avelumab (Bavencio – EMD Serono) and durvalumab (Imfinzi – AstraZeneca), two new immune check point inhibitors, and pembrolizumab (Keytruda – Merck), a checkpoint inhibitor that has been available in the US since 2014, for treatment of locally advanced or metastatic bladder cancer. Nivolumab (Opdivo) and atezolizumab (Tecentriq) were approved earlier for this indication.1

INDICATIONS — All of the immune checkpoint inhibitors are FDA-approved for second-line treatment of locally advanced or metastatic bladder cancer after failure of chemotherapy. Atezolizumab and pembrolizumab can also be used for first-line treatment of patients who are not eligible for cisplatin-containing chemotherapy. All of these drugs received accelerated approvals from the FDA based on tumor response rates ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)
Article code: 1535f
 Electronic, downloadable article - $25